177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

By afschroeder • November 13, 2025

Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Karasik D, Parmisano S, Basehart TV, Brisbane W, Marks L, Rettig MB, Reiter RE, Boutros PC, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J. ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. J Clin Oncol. 2025 Nov 12:JCO2501553. doi: 10.1200/JCO-25-01553. Epub ahead of print. PMID: 41223345.

Tags: Cardiology/Epi, DOM STAT, General Internal Medicine, Hematology/Oncology, Publications, Veterans Administration

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity: Focus on Prevention and Treatment of Cardiometabolic Disease

Anker SD, Ji L, Kindel T, Coats AJ, Ojji D, Barragán AP, Rossing P, Zieroth S, Ahmad S, Usman S, Appannah G, Bailey AL, Bennis[...]

The frequency and impact of previous admissions within 90 days of subsequent hospitalization for acute myocarditis: An analysis of the Nationwide readmission database

Afzal A, Qureshi A, Bozkurt B, Fonarow GC, Lip GYH, Kwok CS. The frequency and impact of previous admissions within 90 days of subsequent hospitalization[...]

Heart Failure Risk in HIV: From Immunodeficiency to Metabolic Complexity

Shakil SS, Hsue PY. Heart Failure Risk in HIV: From Immunodeficiency to Metabolic Complexity. Circ Heart Fail. 2026 Mar 11:e014088. doi: 10.1161/CIRCHEARTFAILURE.126.014088. Epub ahead of[...]